Sen. Warren attacks GSK's decision to shift inhaler from brand to authorized generic

Zachary Brennan

Senior Editor

GSK’s decision to switch patients from its brand-name Flovent inhaler to an authorized generic is an “insidious” tactic that “may cause millions of children” to …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Sen. Warren attacks GSK's decision to shift inhaler from brand to authorized generic

Zachary Brennan

Senior Editor

Sign up to read this article for free.

Former FDA chief calls job cuts ‘haphazard, poorly thought-out’

Novo looks to recoup $830M from hypertension drug partner, claiming fraud

NIH payment cuts are 'reasoned and rational,' government says

After research pivot, Biogen beefs up pipeline with Stoke's late-stage Dravet candidate

Arcus touts early kidney cancer data as Gilead declines option

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Sen. War­ren at­tacks GSK's de­ci­sion to shift in­haler from brand to au­tho­rized gener­ic

Zachary Brennan

Senior Editor

Sign up to read this article for free.

For­mer FDA chief calls job cuts ‘hap­haz­ard, poor­ly thought-out’

No­vo looks to re­coup $830M from hy­per­ten­sion drug part­ner, claim­ing fraud

NIH pay­ment cuts are 'rea­soned and ra­tio­nal,' gov­ern­ment says

Af­ter re­search piv­ot, Bio­gen beefs up pipeline with Stoke's late-stage Dravet can­di­date

Ar­cus touts ear­ly kid­ney can­cer da­ta as Gilead de­clines op­tion

Trust­ed pro­tec­tion: Why the cur­rent meningo­coc­cal vac­ci­na­tion sched­ule shouldn’t change with­out strong ev­i­dence

Sen. Warren attacks GSK's decision to shift inhaler from brand to authorized generic

Former FDA chief calls job cuts ‘haphazard, poorly thought-out’

Novo looks to recoup $830M from hypertension drug partner, claiming fraud

NIH payment cuts are 'reasoned and rational,' government says

After research pivot, Biogen beefs up pipeline with Stoke's late-stage Dravet candidate

Arcus touts early kidney cancer data as Gilead declines option

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence